May 1, 2025
Dataset will advance development of GLP-1 therapies in new indications and accelerate discovery of novel drug targets in patients who are unresponsive to therapies
A press release from Illumina announces a collaboration with Ovation.io to create a significant dataset focused on patients treated with GLP-1 therapies. This dataset integrates clinical information with genomic and proteomic insights from 25,000 patients. The goal is to accelerate the discovery of new therapies, identify additional uses for existing GLP-1 drugs, and find biomarkers for patients who don’t respond to current treatments. The initiative leverages Illumina’s sequencing technology and Ovation’s extensive biobank.
Audio Overview (Google NotebookLM)
(10 minutes 30 seconds)
